Apparent genotype–phenotype mismatch in a patient with MYH9-related disease: When the exception proves the rule

Paolo Gresele; Daniela De Rocco; Loredana Bury; Tiziana Fierro; Anna Maria Mezzasoma; Alessandro Pecci; Anna Savoia

doi:10.1160/TH13-02-0175

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2013; 110(03): 618-620
DOI: 10.1160/TH13-02-0175

Letters to the Editor

Schattauer GmbH

Apparent genotype–phenotype mismatch in a patient with MYH9-related disease: When the exception proves the rule

Authors

Paolo Gresele

¹Division of Internal and Cardiovascular Medicine, Department of Internal Medicine, University of Perugia, Perugia, Italy;
Daniela De Rocco

²Institute for Maternal and Child Health – IRCCS “Burlo Garofolo”, University of Trieste, Trieste, Italy;
Loredana Bury

¹Division of Internal and Cardiovascular Medicine, Department of Internal Medicine, University of Perugia, Perugia, Italy;
Tiziana Fierro

¹Division of Internal and Cardiovascular Medicine, Department of Internal Medicine, University of Perugia, Perugia, Italy;
Anna Maria Mezzasoma

¹Division of Internal and Cardiovascular Medicine, Department of Internal Medicine, University of Perugia, Perugia, Italy;
Alessandro Pecci

³Department of Internal Medicine, IRCCS Policlinico San Matteo Foundation, University of Pavia, Pavia, Italy
Anna Savoia

²Institute for Maternal and Child Health – IRCCS “Burlo Garofolo”, University of Trieste, Trieste, Italy;

Abstract

Volltext

Referenzen

References
1 Seri M, Pecci A, Di Bari F. et al. MYH9-related disease: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness. Medicine 2003; 82: 203-215.
2 Pecci A, Panza E, Pujol-Moix N. et al. Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history of MYH9-related disease. Hum Mutat 2008; 29: 409-417.
3 Balduini CL, Pecci A, Savoia A. Recent advances in the understanding and management of MYH9-related inherited thrombocytopenias. Br J Haematol 2011; 154: 161-174.
4 Pecci A, Biino G, Fierro T. et al. 2012. Alteration of liver enzymes is a feature of the MYH9-related disease syndrome. PLoS One 2012; 07: e35986.
5 Balduini CL, Cattaneo M, Fabris F. et al. Inherited thrombocytopenias: a proposed diagnostic algorithm from the Italian Gruppo di Studio delle Piastrine. Haematologica 2003; 88: 582-592.
6 Savoia A, De Rocco D, Panza E. et al. Heavy chain myosin 9-related disease (MYH9-RD): neutrophil inclusions of myosin-9 as a pathognomonic sign of the disorder. Throm Haemost 2010; 103: 826-832.
7 Kunishima S, Matsushita T, Yoshihara T. et al. First description of somatic mosaicism in MYH9 disorders. Br J Haematol 2005; 128: 360-365.
8 Kunishima S, Takaki K, Ito Y, Saito H. Germinal mosaicism in MYH9 disorders: a family with two affected siblings of normal parents. Br J Haematol 2009; 145: 260-262.
9 Gardner RJM, Sutherland GR. Chromosome abnormalities and genetic counselling. New York: Oxford University Press; 2004
10 Pecci A, Granata A, Fiore CE. et al. Renin-angiotensin system blockade is effective in reducing proteinuria of patients with progressive nephropathy caused by MYH9 mutations (Fechtner-Epstein syndrome). Nephrol Dial Transplant 2008; 23: 2690-2692.
11 Pecci A, Gresele P, Klersy C. et al. Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations. Blood 2010; 116: 5832-5837.